Literature DB >> 1329797

Medulloblastomas and related primitive neuroectodermal brain tumors of childhood recapitulate molecular milestones in the maturation of neuroblasts.

J Q Trojanowski1, T Tohyama, V M Lee.   

Abstract

We review here recent data that have brought into sharper focus a number of important biological properties of the neoplastic cells in childhood primitive neuroectodermal tumors (PNETs) of the central nervous system (CNS). Studies of this group of tumors, as exemplified by posterior fossa medulloblastomas (MBs), suggest that neoplastic cells in PNETs partially recapitulate stages in the maturation of normal human neuroblasts. These findings may contribute to the elucidation of the mechanisms involved in tumor initiation and progression because oncogenes and antioncogenes appear to exert their effects in a cell type-specific manner that also depends on the maturational state of a given cell. Currently, a large body of data suggests that populations of cells in PNETs (e.g., MBs) exhibit one or more molecular defects in the sequence of maturational events leading to the exit of stem cells or partially committed neuron-like precursors from the cell cycle, followed by their terminal differentiation into neurons. This, together with the orchestrated interactions of as yet unidentified oncogenes and antioncogenes in these PNET cells, may represent a cluster of molecular abnormalities that underly the emergence of the highly malignant phenotype that characterizes childhood PNETs.

Entities:  

Mesh:

Year:  1992        PMID: 1329797     DOI: 10.1007/bf03159987

Source DB:  PubMed          Journal:  Mol Chem Neuropathol        ISSN: 1044-7393


  14 in total

1.  Neurotrophin and neurotrophin receptor proteins in medulloblastomas and other primitive neuroectodermal tumors of the pediatric central nervous system.

Authors:  K Washiyama; Y Muragaki; L B Rorke; V M Lee; S C Feinstein; M J Radeke; D Blumberg; D R Kaplan; J Q Trojanowski
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

2.  REST-VP16 activates multiple neuronal differentiation genes in human NT2 cells.

Authors:  A Immaneni; P Lawinger; Z Zhao; W Lu; L Rastelli; J H Morris; S Majumder
Journal:  Nucleic Acids Res       Date:  2000-09-01       Impact factor: 16.971

Review 3.  Genomic stability and instability in different neuroepithelial tumors. A role for chromosome structure?

Authors:  L Manuelidis
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma.

Authors:  R A Segal; L C Goumnerova; Y K Kwon; C D Stiles; S L Pomeroy
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 5.  Cellular and molecular pathology of medulloblastoma.

Authors:  J P Provias; L E Becker
Journal:  J Neurooncol       Date:  1996-07       Impact factor: 4.130

Review 6.  Medulloblastoma: molecular genetics and animal models.

Authors:  Corey Raffel
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

7.  Effects of basic fibroblastic growth factor on the growth of human medulloblastoma xenografts.

Authors:  Pascal Vachon; Christiane Girard; Yves Théorêt
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

8.  A medulloblastoma showing an unusually long doubling time: reflection of its singular nature.

Authors:  Omer Doron; Jacob Zauberman; Ze'ev Feldman
Journal:  Childs Nerv Syst       Date:  2016-01-06       Impact factor: 1.475

9.  Expression of the splicing regulator polypyrimidine tract-binding protein in normal and neoplastic brain.

Authors:  Ian E McCutcheon; Stephen J Hentschel; Gregory N Fuller; Wei Jin; Gilbert J Cote
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

10.  Co-expression of low molecular weight neurofilament protein and glial fibrillary acidic protein in established human glioma cell lines.

Authors:  T Tlhyama; V M Lee; J Q Trojanowski
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.